We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Clearstar Inc. | CLSU | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 39.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 39.50 | 39.50 |
| Top Posts |
|---|
Posted at 17/7/2020 07:51 by brummy_git Comment on social media herehxxps://www.linkedin |
Posted at 28/5/2020 08:31 by 2toptrader This is definitely good value at these levels, back to pre Covid-19 rns.Two other companies on AIM providing Covid-19 services : FLTA - decontamination & cleaning Revenue c £14 mil versus Market cap £ 33 mil REAT- deep cleaning sevices Revenue £ 3.1 mil versus Market cap £ 7 mil CLSU - Covid testing Revenue c £ 19 mil versus mc £ 15 mil CLSU clearly undervalued at 0.8 revenue. Easy double in my view, a bit puzzled by the weakness here. |
Posted at 21/5/2020 08:31 by brummy_git Agreed - updated CLSU commentary herehxxps://www.linkedin |
Posted at 06/5/2020 08:01 by edmonda Results FY19 were in line with revs +14%. COVID-19 has led to huge US job losses since and major US Labs have focused on the virus, but CLSU is tightening its belt until economic normality returns, when it is well placed for what could be a massive demand surge.Full research note from Equity Development out here: |
Posted at 11/2/2020 08:37 by brummy_git Likewise. Plenty of number crunching here too on CLSU. |
Posted at 17/12/2019 07:47 by brummy_git Temporary lull in financial screening volumes at ClearStar in Q4, which has shaved $400k off our 2019 adjusted EBITDA (pre SBPs) forecast. Likewise the valuation falls to 115p/share from 135p.Nonetheless if going forward, CLSU can use this minor setback as the catalyst to increase EBITDA drop through rates - say by possibly reducing indirect channel attrition, lifting MIS prices and/or trimming the cost base. Whilst simultaneously maintaining its strong double digit top line growth, then we think investors will all look back in 12 months' time, and see this has a L/T positive, despite the S/T pain. New research here: hxxps://www.equityde |
Posted at 19/9/2019 14:33 by edmonda interview with CLSU management discussing interims |
Posted at 08/8/2019 07:42 by equitydev Twitter is an incredibly useful service, albeit it definitely makes it much harder to invest, when whole industries can be rocked overnight by a simple tweet from the White House. However what President Trump has been 100% consistent on, is putting ‘America First’.Indeed we believe this policy should continue to support the US as the best performing G7 economy heading into the Nov’20 Presidential Elections, and remain the ‘destination of choice’ for many fund managers. Fortunately too for UK investors, there are US domestically-focused companies listed right here in London. Take ClearStar, a tech-enabled background & medical screening (MIS) specialist, based in Atlanta (Georgia) that is both expanding rapidly & materially undervalued. Today the firm said that it had backed up June’s “highest ever monthly revenue [Est +29% organically]” with another blistering performance in July. Not only breaking the $1m/month barrier at its leading MIS division, but also delivering total revenues of $2.25m, up approx. 26%-30% LFL. Growth is being driven by the group’s best-in-class mobile software, on-boarding of clients, contract wins and up/X-selling. Augmented by favourable macro tailwinds, such as the ongoing popularity of the gig economy, crackdowns on illegal workers & legalisation of cannabis for recreational use. Consequently we are becoming increasingly confident that CLSU will hit (& perhaps even exceed) our conservative FY19 revenue forecast of $23.0m (14.4% LFL), and reiterate the 135p/share valuation. In fact if this momentum is maintained, then there should be scope for future upgrades in due course. New research freely available here: hxxps://www.equityde |
Posted at 20/4/2018 17:51 by brummy_git Encouraging too, to see the Chairman picking up another line of stock"ClearStar (AIM: CLSU), the technology and service provider to the background check industry, announces that Barney Quinn, Non-executive Chairman of the Company, purchased 33,660 ordinary shares of $0.0001 in the Company ("Ordinary Shares") on 18 April 2018 at a price of 44 pence per Ordinary Share. Following this purchase, Mr. Quinn holds 278,215 Ordinary Shares, representing approximately 0.77% of the issued share capital of the Company." |
Posted at 12/7/2017 09:31 by edmonda ClearStar Inc write up by Paul Hill at Equity Development:Don’t you just love ‘Tech’? Churning out irresistible growth rates, profit margins and cashflows, allied to robust visibility and high client retention. A compelling mix. The only problem is that many others do as well, pushing valuations to often nose-bleed levels. However, what if it was possible to find a company, expanding at >10% pa (see below), yet trading at a mere 1.1x EV/sales vs 2x-4x for the wider sector. Interested? I was too on coming across ClearStar Inc (AIM: CLSU). A little-known £16m market cap stock, providing automated job screening and alcohol/drug testing services. Areas enjoying buoyant demand from the rise of the ‘gig’ economy (Uber/Deliveroo), government clampdowns on illegal workers and ongoing healthy employment levels. In fact, I was so impressed that I snapped up a 3.6% stake earlier this year (RNS)... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
